Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Leukemia

Free Subscription Articles published in Hematol Oncol Clin North Am Retrieve available abstracts of 25 articles: HTML format

Single Articles

August 2021
1. BROWN JR
   Chronic Lymphocytic Leukemia: So Much Progress, Still Challenges Ahead.
   Hematol Oncol Clin North Am. 2021;35:xiii-xiv.
   PubMed    
   
   
   
2. SHADMAN M, Maloney DG
   Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
   Hematol Oncol Clin North Am. 2021;35:847-862.
   PubMed     Abstract available
   
   
   
3. SUN C, Wiestner A
   Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
   Hematol Oncol Clin North Am. 2021;35:827-845.
   PubMed     Abstract available
   
   
   
4. LAMPSON BL, Brown JR
   The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
   Hematol Oncol Clin North Am. 2021;35:807-826.
   PubMed     Abstract available
   
   
   
5. THOMPSON MC, Mato AR
   Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
   Hematol Oncol Clin North Am. 2021;35:793-806.
   PubMed     Abstract available
   
   
   
6. LASICA M, Tam CS
   Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
   Hematol Oncol Clin North Am. 2021;35:761-773.
   PubMed     Abstract available
   
   
   
7. DING W
   The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.
   Hematol Oncol Clin North Am. 2021;35:739-759.
   PubMed     Abstract available
   
   
   
8. CHERNG HJ, Jain N
   First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
   Hematol Oncol Clin North Am. 2021;35:725-738.
   PubMed     Abstract available
   
   
   
9. VLACHONIKOLA E, Sofou E, Chatzidimitriou A, Stamatopoulos K, et al
   The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications.
   Hematol Oncol Clin North Am. 2021;35:687-702.
   PubMed     Abstract available
   
   
   
10. NG A, Chiorazzi N
    Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia.
    Hematol Oncol Clin North Am. 2021;35:665-685.
    PubMed     Abstract available
    
    
    May 2021
11. AL-SAWAF O, Seymour JF, Kater AP, Fischer K, et al
    Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
    Hematol Oncol Clin North Am. 2021 May 15. pii: S0889-8588(21)00039.
    PubMed     Abstract available
    
    
    April 2020
12. WINER ES
    Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment.
    Hematol Oncol Clin North Am. 2020;34:449-463.
    PubMed     Abstract available
    
    
    
13. GARCIA JS
    Prospects for Venetoclax in Myelodysplastic Syndromes.
    Hematol Oncol Clin North Am. 2020;34:441-448.
    PubMed     Abstract available
    
    
    February 2020
14. BALIGA S, Yock TI
    Pediatric Cancer.
    Hematol Oncol Clin North Am. 2020;34:143-159.
    PubMed     Abstract available
    
    
    August 2018
15. SAVAGE SA, Walsh MF
    Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Cancer Surveillance in Fanconi Anemia.
    Hematol Oncol Clin North Am. 2018;32:657-668.
    PubMed     Abstract available
    
    
    
16. SCHAEFER EJ, Lindsley RC
    Significance of Clonal Mutations in Bone Marrow Failure and Inherited Myelodysplastic Syndrome/Acute Myeloid Leukemia Predisposition Syndromes.
    Hematol Oncol Clin North Am. 2018;32:643-655.
    PubMed     Abstract available
    
    
    
17. MCREYNOLDS LJ, Calvo KR, Holland SM
    Germline GATA2 Mutation and Bone Marrow Failure.
    Hematol Oncol Clin North Am. 2018;32:713-728.
    PubMed     Abstract available
    
    
    
18. SIEFF CA
    Introduction to Acquired and Inherited Bone Marrow Failure.
    Hematol Oncol Clin North Am. 2018;32:569-580.
    PubMed     Abstract available
    
    
    December 2017
19. ROSE-INMAN H, Kuehl D
    Acute Leukemia.
    Hematol Oncol Clin North Am. 2017;31:1011-1028.
    PubMed     Abstract available
    
    
    August 2017
20. GARCIA JS, Stone RM
    The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
    Hematol Oncol Clin North Am. 2017;31:663-680.
    PubMed     Abstract available
    
    
    
21. PATEL AB, O'Hare T, Deininger MW
    Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
    Hematol Oncol Clin North Am. 2017;31:589-612.
    PubMed     Abstract available
    
    
    
22. RADICH JP, Mauro MJ
    Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
    Hematol Oncol Clin North Am. 2017;31:577-587.
    PubMed     Abstract available
    
    
    
23. GHIAUR G, Levis M
    Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.
    Hematol Oncol Clin North Am. 2017;31:681-692.
    PubMed     Abstract available
    
    
    April 2017
24. SUD A, Dearden C
    T-cell Prolymphocytic Leukemia.
    Hematol Oncol Clin North Am. 2017;31:273-283.
    PubMed     Abstract available
    
    
    
25. DITTUS C, Sloan JM
    Adult T-cell Leukemia/Lymphoma: A Problem Abroad and at Home.
    Hematol Oncol Clin North Am. 2017;31:255-272.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: